Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity

Kerri Bouwman, Ji Qiu, Heping Zhou, Mark Schotanus, Leslie A. Mangold, Robert Vogt, Erik Erlandson, John Trenkle, Alan W. Partin, David Misek, Gilbert S. Omenn, Brian B. Haab, Samir Hanash

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The broad characterization of the immune responses elicited by tumors has valuable applications in diagnostics and basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Two-dimensional liquid chromatography was used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions. These fractions were spotted in microarrays on coated microscope slides, and the microarrays were incubated individually with serum samples from 25 men with prostate cancer and 25 male controls. The amount of immunoglobulin bound to each fraction by each serum sample was quantified. Statistical analysis revealed that 38 of the fractions had significantly higher levels of immunoglobulin binding in the prostate cancer samples compared to the controls. Two fractions showed higher binding in the control samples. The significantly higher immunoglobulin reactivity from the prostate cancer samples may reflect a strong immune response to the tumors in the prostate cancer patients. We used multivariate analysis to classify the samples as either prostate cancer or control. In a cross-validation study, recursive partitioning classified the samples with 84% accuracy. A decision tree with two levels of partitioning classified the samples with 98% accuracy. Additional studies will allow further characterization of tumor antigens in prostate cancer and their significance for diagnosis. These results suggest that microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis.

Original languageEnglish (US)
Pages (from-to)2200-2207
Number of pages8
JournalProteomics
Volume3
Issue number11
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Microarrays
Tumors
Prostatic Neoplasms
Cells
Immunoglobulins
Serum
Neoplasm Antigens
Neoplasms
Proteins
Liquid chromatography
Decision trees
Statistical methods
Microscopes
Protein Array Analysis
Decision Trees
Validation Studies
Liquid Chromatography
Antibodies
Multivariate Analysis
Cell Line

Keywords

  • Protein microarrays
  • Tumor antigens
  • Two-dimensional chromatography

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. / Bouwman, Kerri; Qiu, Ji; Zhou, Heping; Schotanus, Mark; Mangold, Leslie A.; Vogt, Robert; Erlandson, Erik; Trenkle, John; Partin, Alan W.; Misek, David; Omenn, Gilbert S.; Haab, Brian B.; Hanash, Samir.

In: Proteomics, Vol. 3, No. 11, 11.2003, p. 2200-2207.

Research output: Contribution to journalArticle

Bouwman, K, Qiu, J, Zhou, H, Schotanus, M, Mangold, LA, Vogt, R, Erlandson, E, Trenkle, J, Partin, AW, Misek, D, Omenn, GS, Haab, BB & Hanash, S 2003, 'Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity', Proteomics, vol. 3, no. 11, pp. 2200-2207. https://doi.org/10.1002/pmic.200300611
Bouwman, Kerri ; Qiu, Ji ; Zhou, Heping ; Schotanus, Mark ; Mangold, Leslie A. ; Vogt, Robert ; Erlandson, Erik ; Trenkle, John ; Partin, Alan W. ; Misek, David ; Omenn, Gilbert S. ; Haab, Brian B. ; Hanash, Samir. / Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. In: Proteomics. 2003 ; Vol. 3, No. 11. pp. 2200-2207.
@article{ab6cb4c3bc4c426480d9d3fd35acab02,
title = "Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity",
abstract = "The broad characterization of the immune responses elicited by tumors has valuable applications in diagnostics and basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Two-dimensional liquid chromatography was used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions. These fractions were spotted in microarrays on coated microscope slides, and the microarrays were incubated individually with serum samples from 25 men with prostate cancer and 25 male controls. The amount of immunoglobulin bound to each fraction by each serum sample was quantified. Statistical analysis revealed that 38 of the fractions had significantly higher levels of immunoglobulin binding in the prostate cancer samples compared to the controls. Two fractions showed higher binding in the control samples. The significantly higher immunoglobulin reactivity from the prostate cancer samples may reflect a strong immune response to the tumors in the prostate cancer patients. We used multivariate analysis to classify the samples as either prostate cancer or control. In a cross-validation study, recursive partitioning classified the samples with 84{\%} accuracy. A decision tree with two levels of partitioning classified the samples with 98{\%} accuracy. Additional studies will allow further characterization of tumor antigens in prostate cancer and their significance for diagnosis. These results suggest that microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis.",
keywords = "Protein microarrays, Tumor antigens, Two-dimensional chromatography",
author = "Kerri Bouwman and Ji Qiu and Heping Zhou and Mark Schotanus and Mangold, {Leslie A.} and Robert Vogt and Erik Erlandson and John Trenkle and Partin, {Alan W.} and David Misek and Omenn, {Gilbert S.} and Haab, {Brian B.} and Samir Hanash",
year = "2003",
month = "11",
doi = "10.1002/pmic.200300611",
language = "English (US)",
volume = "3",
pages = "2200--2207",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "11",

}

TY - JOUR

T1 - Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity

AU - Bouwman, Kerri

AU - Qiu, Ji

AU - Zhou, Heping

AU - Schotanus, Mark

AU - Mangold, Leslie A.

AU - Vogt, Robert

AU - Erlandson, Erik

AU - Trenkle, John

AU - Partin, Alan W.

AU - Misek, David

AU - Omenn, Gilbert S.

AU - Haab, Brian B.

AU - Hanash, Samir

PY - 2003/11

Y1 - 2003/11

N2 - The broad characterization of the immune responses elicited by tumors has valuable applications in diagnostics and basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Two-dimensional liquid chromatography was used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions. These fractions were spotted in microarrays on coated microscope slides, and the microarrays were incubated individually with serum samples from 25 men with prostate cancer and 25 male controls. The amount of immunoglobulin bound to each fraction by each serum sample was quantified. Statistical analysis revealed that 38 of the fractions had significantly higher levels of immunoglobulin binding in the prostate cancer samples compared to the controls. Two fractions showed higher binding in the control samples. The significantly higher immunoglobulin reactivity from the prostate cancer samples may reflect a strong immune response to the tumors in the prostate cancer patients. We used multivariate analysis to classify the samples as either prostate cancer or control. In a cross-validation study, recursive partitioning classified the samples with 84% accuracy. A decision tree with two levels of partitioning classified the samples with 98% accuracy. Additional studies will allow further characterization of tumor antigens in prostate cancer and their significance for diagnosis. These results suggest that microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis.

AB - The broad characterization of the immune responses elicited by tumors has valuable applications in diagnostics and basic research. We present here the use of microarrays of tumor-derived proteins to profile the antibody repertoire in the sera of prostate cancer patients and controls. Two-dimensional liquid chromatography was used to separate proteins from the prostate cancer cell line LNCaP into 1760 fractions. These fractions were spotted in microarrays on coated microscope slides, and the microarrays were incubated individually with serum samples from 25 men with prostate cancer and 25 male controls. The amount of immunoglobulin bound to each fraction by each serum sample was quantified. Statistical analysis revealed that 38 of the fractions had significantly higher levels of immunoglobulin binding in the prostate cancer samples compared to the controls. Two fractions showed higher binding in the control samples. The significantly higher immunoglobulin reactivity from the prostate cancer samples may reflect a strong immune response to the tumors in the prostate cancer patients. We used multivariate analysis to classify the samples as either prostate cancer or control. In a cross-validation study, recursive partitioning classified the samples with 84% accuracy. A decision tree with two levels of partitioning classified the samples with 98% accuracy. Additional studies will allow further characterization of tumor antigens in prostate cancer and their significance for diagnosis. These results suggest that microarrays of fractionated proteins could be a powerful tool for tumor antigen discovery and cancer diagnosis.

KW - Protein microarrays

KW - Tumor antigens

KW - Two-dimensional chromatography

UR - http://www.scopus.com/inward/record.url?scp=0242440011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242440011&partnerID=8YFLogxK

U2 - 10.1002/pmic.200300611

DO - 10.1002/pmic.200300611

M3 - Article

C2 - 14595819

AN - SCOPUS:0242440011

VL - 3

SP - 2200

EP - 2207

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 11

ER -